---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-067778"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:27.874709+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading

## Summary
- FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.
- Oncology subsidiary merged with TenX Keane; Citius Oncology (Nasdaq: CTOR) starts trading Aug 13, 2024.
- Mino-Lok Phase 3 trial met primary and secondary endpoints; cash $17.9M as of June 30, 2024, with runway through Dec 2024.
- Net loss $10.6M ($0.06/sh) for Q3 ended June 30, 2024, vs $8.5M ($0.06/sh) a year ago; R&D expenses $2.8M.

## SEC filing metadata
- accession: 0001213900-24-067778
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/0001213900-24-067778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024067778/ea0211123-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-067778
- JSON: https://secwatch.observer/filing/0001213900-24-067778.json
- Plain text: https://secwatch.observer/filing/0001213900-24-067778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.